Education
About Us
Working with TipRanks
Follow Us
Cumberland Pharmaceuticals Inc (CPIX)
NASDAQ:CPIX
RESEARCH TOOLSreports
Total Valuation
Cumberland Pharmaceuticals has a market cap or net worth of $84.83M. The enterprise value is $33.97M.
Market Cap$84.83M
Enterprise Value$33.97M
Share Statistics
Cumberland Pharmaceuticals has 14,961,137 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding14,961,137
Owned by Insiders41.50%
Owned by Institutions12.13%
Financial Efficiency
Cumberland Pharmaceuticals’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -14.32%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.09
Return on Invested Capital (ROIC)-14.32%
Return on Capital Employed (ROCE)-0.16
Revenue Per Employee416.13K
Profits Per Employee-70.81B
Employee Count91
Asset Turnover0.50
Inventory Turnover1.65
Valuation Ratios
The current PE Ratio of Cumberland Pharmaceuticals is -5.14. Cumberland Pharmaceuticals’s PEG ratio is -2.20.
PE Ratio-5.14
PS Ratio0.00
PB Ratio0.90
Price to Fair Value1.46
Price to FCF5.14
Price to Operating Cash Flow3.88
PEG Ratio-2.20
Income Statement
In the last 12 months, Cumberland Pharmaceuticals had revenue of 37.87M and earned -6.48M in profits. Earnings per share was -0.46.
Revenue37.87M
Gross Profit26.38M
Operating Income-7.10M
Pretax Income-6.47M
Net Income-6.48M
EBITDA182.42K
Earnings Per Share (EPS)-0.46
Cash Flow
In the last 12 months, operating cash flow was 5.42M and capital expenditures -80.43K, giving a free cash flow of 5.34M billion.
Operating Cash Flow5.42M
Free Cash Flow5.34M
Free Cash Flow per Share0.36
Dividends & Yields
Cumberland Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.33
52-Week Price Change251.68%
50-Day Moving Average4.92
200-Day Moving Average3.14
Relative Strength Index (RSI)49.00
Average Volume (3m)35.31K
Important Dates
Cumberland Pharmaceuticals upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
Cumberland Pharmaceuticals as a current ratio of 1.15, with Debt / Equity ratio of 57.79%
Current Ratio1.15
Quick Ratio1.03
Debt to Market Cap0.46
Net Debt to EBITDA14.30
Interest Coverage Ratio-11.73
Taxes
In the past 12 months, Cumberland Pharmaceuticals has paid -22.67K in taxes.
Income Tax-22.67K
Effective Tax Rate<0.01
Enterprise Valuation
Cumberland Pharmaceuticals EV to EBITDA ratio is 196.97, with an EV/FCF ratio of -45.37.
EV to Sales0.95
EV to EBITDA196.97
EV to Free Cash Flow-45.37
EV to Operating Cash Flow-58.69
Balance Sheet
Cumberland Pharmaceuticals has $15.11M in cash and marketable securities with $10.44M in debt, giving a net cash position of -$4.67M billion.
Cash & Marketable Securities$15.11M
Total Debt$10.44M
Net Cash-$4.67M
Net Cash Per Share-$0.31
Tangible Book Value Per Share$0.26
Margins
Gross margin is 78.29%, with operating margin of -18.75%, and net profit margin of -17.11%.
Gross Margin78.29%
Operating Margin-18.75%
Pretax Margin-17.08%
Net Profit Margin-17.11%
EBITDA Margin0.48%
EBIT Margin-15.48%
Analyst Forecast
The average price target for Cumberland Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast5.82%
EPS Growth Forecast59.86%